TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06494462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality training
Description: students will watch a video about subcutaneous injection or students will play a about subcutaneous injection by virtual reality glasses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality training
Description: students will watch a video about subcutaneous injection or students will play a about subcutaneous injection by virtual reality glasses
Study: NCT05784532

Intervention type: DEVICE
Intervention: STERN FIX
Description: Sternotomy closure with STERN FIX and supplemented with wires
Study: NCT05908292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Scar Tissue Self-Scar Massage
Description: Self scar-massage intervention of healed pelvic floor scar tissue for 5 minutes, 3x/week for 6 weeks.
Study: NCT05850585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation(FMT)
Description: Subjects will receive FMT capsules (10\^12 Colony-Forming Units(CFU)/capsule) in addition to their usual antipsychotics treatment. Subjects will continue to receive FMT capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a placebo capsule with the same color, appearance, and smell as the FMT capsule, in addition to their usual antipsychotics treatment. Placebo capsules contained the food probiotic Lactobacillus (10\^12 CFU per capsule). Subjects will continue to receive placebo capsules for 8 weeks. During this period, both groups could receive first-line atypical antipsychotics recommended by current treatment guidelines.
Study: NCT05349643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMB-05X
Description: A fully human monoclonal immunoglobulin (IgG2) directed against c-fms
Study: NCT05524961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: Regularly-timed exposure to 10,000lux bright light therapy for 60minutes a day for six weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated negative ion generator
Description: Regularly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated negative ion generator
Description: Randomly-timed exposure to an inactivated negative ion generator for 60minutes a day for six weeks
Study: NCT05693363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AURA10 Specimen Imager
Description: High-resolution specimen imaging using the AURA10 PET-CT specimen imager during thoracic surgery.
Study: NCT04855578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Hopsital Patient Educational Brochure
Description: The participant's medication list will be identified from the pharmacy database and validated with the participant's best possible medication history taken at time of admission by a pharmacist. Eligibility will be confirmed by the participant's treating medical team with support from the study investigators. Participants who are enrolled during the intervention phase will receive an educational brochure about the risks of chronic gabapentinoid use, and about how to safely discontinue use. The brochure is written using a sixth-grade vocabulary and has been validated in both English and French for comprehension and readability, including for people with mild cognitive impairment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Education about Gabapentinoid Prescription
Description: An educational session about the purpose of the study and risks of gabapentinoid prescription will be delivered to physicians (staff and medical residents) on each study unit at both sites during the intervention period. The educational session will include a presentation by the chief of the medical service at the monthly teaching rounds, and an electronic message will be sent to all physicians on the medical service. Physicians will also be presented a brief overview of the educational brochure.
Study: NCT05942911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IHL-675A
Description: Combination product containing CBD and HCQ UniGel™ technology by ProCaps®. IHL-675A consists of a solid, film coated HCQ tablet that is contained within a CBD oil solution gel cap. Each IHL-675A gel cap contains 75 mg of CBD and 100 mg HCQ.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Formulated using UniGel™ technology by ProCaps®. The CBD soft gel capsules contain 75 mg CBD oil solution. These capsules look identical to the IHL-675A UniGel™ capsules, to aid double-blinding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Formulated using UniGel™ technology by ProCaps®. The soft gel capsules each contain a 100 mg HCQ tablet. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulated using UniGel™ technology by ProCaps®. The soft gel capsules contain the inactive ingredients of the IHL-675A capsules and no active ingredients. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
Study: NCT05436314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual Lymphatic Drainage (MLD) is applied towards the flow direction of lymph vessels with special hand movements. MLD is made with very light, completely painless and rhythmic translational movements of the skin. MLD, by expert and trained physiotherapists (G.K, H.K) in this field. It will be applied with the techniques defined by Dr. Vodder. MLD ( to the neck region, abdominal region, axillary and inguinal lymph nodes) will be applied by following the lymphatic pathways specific to the anterior and posterior trunk, respectively. The treatment session will take approximately 45 minutes. It will be applied 5 days a week during 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical treatment
Description: The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Medical treatment
Description: The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manual Lymphatic Drainage
Description: Sham MLD will be administered by MLD-trained physiotherapists (G.K, H.K) with a protocol that is far from techniques that reveal the physiological effects of MLD. Sham application consists of applications that do not follow the lymphatic pathways from distal to proximal to the trunk, neck, and abdominal region, and superficial breathing. The session will take approximately 45 minutes.
Study: NCT05358509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Pregnant participants randomized to intervention arm 1 will receive a single dose of ferric carboxymaltose having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside
Description: Pregnant participants randomized to intervention arm 1 will receive a single dose of iron isomaltoside having 1000mg of iron if they weigh over 50kg. If a participant is under 50kg, they will receive a lower dose as determined by a formula used by the manufacturer (20mg iron/kg body weight). This will be given ideally immediately after randomization, sometime between 14 weeks and 17 weeks of pregnancy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Sulfate
Description: Pregnant participants randomized to the oral iron arm will be given 200 ferrous sulphate tablets with 60mg elemental iron each, immediately after randomization, and instructed to take two per day (one in the morning and one at night) throughout the remainder of their pregnancy.
Study: NCT06449144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness education
Description: The mindfulness-based stress reduction method was examined and a two-step mindfulness education is planned. To reveal the experience of pain: It was planned to conduct interviews with the participants to realize what they think about the pain they have experienced before or what they think about the pain they have experienced here and now, what emotions they have, and their experiences related to their coping processes with pain. Participants will be encouraged to notice negative thoughts that could impact their coping with pain negatively, and they will be provided with education on the benefits of managing the process of changing these negative thoughts. Attempts will be made to establish positive thinking. Attention: Recognizing the relationship between pain sensation and attention and encouraging its expression is included in the intervention. Information on distraction was given and two exercises we planned to increase the level of awareness.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness education
Description: The mindfulness-based stress reduction method was examined and a two-step mindfulness education is planned. To reveal the experience of pain: It was planned to conduct interviews with the participants to realize what they think about the pain they have experienced before or what they think about the pain they have experienced here and now, what emotions they have, and their experiences related to their coping processes with pain. Participants will be encouraged to notice negative thoughts that could impact their coping with pain negatively, and they will be provided with education on the benefits of managing the process of changing these negative thoughts. Attempts will be made to establish positive thinking. Attention: Recognizing the relationship between pain sensation and attention and encouraging its expression is included in the intervention. Information on distraction was given and two exercises we planned to increase the level of awareness.
Study: NCT06331767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mSYNC
Description: mSYNC in an mHealth HIV prevention intervention to be initially delivered at point-of-care during a visit to the emergency department with continued on demand access to intervention app at home. Taking a behavioral medicine approach, mSYNC simulates hospital-based consultation \& liaison psychology service by intervening on interrelated health risk behaviors, mental health issues, and structural/treatment needs. The mHealth app includes modules with motivational interviewing for HIV/drug use risk behaviors, cognitive behavioral therapy for transdiagnostic psychological coping skills, referral system for needed hospital-based services (mental health/drug use treatment; HIV prevention; social services), and access to geolocated resources.
Study: NCT06090669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: Imatinib at 100-400 mg PO QD based on arm assignment/dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Description: Imatinib at 100-400 mg PO QD based on arm assignment/dose level

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruSight Oncology
Description: Assay sequencing platform to identify pathogenic genetic mutations in DNA and RNA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruSight Oncology
Description: Assay sequencing platform to identify pathogenic genetic mutations in DNA and RNA
Study: NCT06362694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib + Trametinib
Description: Dabrafenib is an inhibitor of some mutated forms of BRAF kinases. Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. Dabrafenib and trametinib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of dabrafenib 623 and trametinib in combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumors.
Study: NCT05371613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idursulfase
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idursulfase
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idursulfase
Description: Intravenous repeating dose
Study: NCT05938907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concentrated growth factor
Description: Implanting concentrated growth factor into the area of root apical bone defect

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone substitute
Description: Implanting bone substitute into the area of root apical bone defect

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: concentrated growth factor + bone substitute
Description: Implanting concentrated growth factor + bone substitute into the area of root apical bone defect
Study: NCT05603312

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-GAD Dose 1
Description: Bilateral infusion of AAV-GAD Dose 1

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-GAD Dose 2
Description: Bilateral infusion of AAV-GAD Dose 2

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Surgery
Description: Sham infusion
Study: NCT06481488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2086
Description: E2086 tablets.
Study: NCT04933656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: one 24 hr cycle of meals at a 2000 kcal level
Description: 50g added sugar

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: one 24 hr cycle of meals at a 2000 kcal level + one serving sugar sweetened beverage
Description: 90 grams added sugar
Study: NCT04583787

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi myocardial perfusion SPECT
Description: 82Rb-PET/CT with CT based coronary angiography (CCTA) as part of clinical care at Day 1
Study: NCT06190730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voice-Assisted Remote Symptom Monitoring System (VARSMS)
Description: Utilizing an Alexa Skill activated via an Amazon Echo Dot device, this system will administer two patient-reported outcomes measures to subjects. This will not be used as basis for diagnosis, nor for any clinical intervention.
Study: NCT06516952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT05784753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART Camp
Description: Participants will meet with an in-person coach at the medical fitness center: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a 1-hour group-based exercise training and coaching).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART Camp Connect
Description: Participants will meet with a virtual coach from the medical fitness center via videoconferencing: Months 1-3 weekly for 30 minutes; Months 4-12 every other week for 15 minutes (on alternate weeks, participants will attend a virtual 1-hour group-based exercise training and coaching session via videoconferencing).
Study: NCT06453915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DPA-714
Description: positron emission tomography scan using 18F-DPA-714 as an imaging tracer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: positron emission tomography scan using 18F-FDG as an imaging tracer.
Study: NCT04979039

Intervention type: OTHER
Intervention: analgesia nociception index (ANI) monitoring
Description: The ANI monitor starts lying on the bed in the waiting area before entering the operating room, and the monitoring period should be at least 15 minutes. After entering the operating room, monitoring begins again and is maintained during the operation.
Study: NCT06274749

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Urolithin A
Description: Urolithin A (UA) is a widely available dietary supplement devoid of any known sided effects that is reported to improve mitochondrial function. The UA substance used in this investigation is regulated under Generally Recognized as Safe (GRAS) by the US FDA (GRN No. 000791) (https://www.fda.gov/media/120300/download) and is being advertised and sold as an oral supplement. The daily dose (1 gram) and duration (8 weeks) have already been tested in previous clinical trials.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will consist of methylcellulose and will appear identical to the active supplement. The placebo will be provided by the manufacturer of Urolithin A.
Study: NCT04583787

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 82Rb-Chloride myocardial perfusion PET with CCTA
Description: stress-rest 99mTc-sestamibi myocardial perfusion SPECT, performed subsequent to 99mTc-sestamibi myocardial perfusion SPECT at Day 2
Study: NCT04933656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: one 24 hr cycle of meals at a 2000 kcal level + two servings sugar sweetened beverage
Description: 130 grams added sugar
Study: NCT06552754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motion Reset
Description: virtual reality-based experiential, sensory intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: virtual reality-based experiential, sensory experience without intervention
Study: NCT05322512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: All enrolled participants will be allocated to undergo one 18F-FDG PET/CT scan.
Study: NCT05006716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Orally administered
Study: NCT05964504

Intervention type: PROCEDURE
Intervention: Blood Specimen
Description: Blood will be drawn via venipuncture
Study: NCT06481488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E2086 matched placebo tablets.
Study: NCT06779474

Intervention type: PROCEDURE
Intervention: Laparoscopic ALPPS
Description: Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy
Study: NCT06779409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back squat
Description: 2 sets of 3 repetitions of a back squat, set to 85% of the 1 repetition maximum weight
Study: NCT06330064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan
Description: Intravenous administration